TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Apr 12, 2021 13:16 JST
Source:
Eisai
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
TOKYO, Apr 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis (LF) has received the Animation Award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021.
ISNTD Festival is an annual event aiming to increase awareness about neglected tropical diseases (NTDs) and this year marks the 5th ISNTD Festival. At the ISNTD Festival Awards, which accompanies this festival, outstanding projects will be selected and awarded in each of the seven categories of animation, app, art, awareness campaign, mass media, photo, and video, related to NTDs.
The award-winning animation "Leave No One Behind" features the 10-year LF elimination activities of Eisai and its global partners which have been implemented since Eisai signed a joint statement with the World Health Organization (WHO) for the LF elimination in 2010. The animation highlights the feelings, thoughts and sufferings of patients which were perceived through activities for free provision of medicines and disease awareness. In addition, the animation highlights tremendous efforts of global partners including Eisai dedicated for drug delivery to remote regions, disease awareness activities for residents in endemic regions and support for mass drug administrations (MDAs), in order to make necessary medicines available to those who need them.
Eisai has been manufacturing diethylcarbamazine (DEC tablets), one of the LF treatments, at its Vizag Plant in India and has been providing to LF endemic countries for free since 2013. We have provided 2.01 billion DEC tablets to 28 countries and contributed to LF elimination in Egypt, Kiribati, Thailand and Sri Lanka. We have also been collaborating with global partners on disease awareness for LF and support for implementation of MDAs necessary for the LF elimination. Eisai announced to continue providing DEC tablets for free to endemic countries that need DEC until LF is eliminated in these countries.
By accelerating the development of new medicines for infectious diseases and NTDs including LF which are endemic in developing and emerging countries via leveraging partnerships, together with implementing activities to improve access to medicines including raising disease awareness locally and implementing price setting models that take income levels into account, Eisai strives to further contribute to increasing the benefits for patients and their families worldwide.
Media Inquiries:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
September 08 2025 16:49 JST
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
September 04 2025 09:56 JST
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
September 03 2025 10:32 JST
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
September 01 2025 12:44 JST
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
August 29 2025 17:17 JST
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
August 25 2025 18:30 JST
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
August 18 2025 08:11 JST
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31 2025 17:27 JST
More Press release >>
Latest Press Release
Mitsubishi Motors Launches the All-New Eclipse Cross Electric Vehicle for the European Market
Sep 19, 2025 00:58 JST
Mitsubishi Motors to Begin Sales of All-New Delica Mini and eK Space in Japan in October
Sep 19, 2025 00:50 JST
Upgraded GR Corolla Set for Japan Launch
Sep 19, 2025 00:48 JST
Honda Koraidon Ride on Experience and Onboard Showrun to be Held at Honda Collection Hall
Sep 19, 2025 00:42 JST
Mitsubishi Motors Increases Investment Stake in Australian Automotive Financial Services Company to 19.93%
Sep 19, 2025 00:27 JST
MHI Is Awarded Contract for 20 Units of the Outer Vertical Target for the Divertor Used in the ITER in Southern France
Sep 19, 2025 00:16 JST
NTT and Mitsubishi Heavy Industries Achieved World's Highest Efficiency in Laser Wireless Power Transmission under Atmospheric Turbulence
Sep 19, 2025 00:00 JST
Definitive agreement to implement a joint mine plan between Los Bronces and Andina copper mines
Sep 17, 2025 18:57 JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
Sep 17, 2025 18:20 JST
Honda Announces New Electric Motorcycle "Honda WN7" in Europe
Sep 17, 2025 17:46 JST
EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes
Sep 17, 2025 09:00 JST
Honda Develops New "Chemical Sorting" Technology to Separate Solid Contaminants from Waste Plastics Derived from End-of-life Automobiles
Sep 16, 2025 15:00 JST
NEC Publishes ESG Initiatives Supporting Sustainable Growth of Companies and Society in "ESG Databook 2025"
Sep 16, 2025 14:00 JST
JSR Corporation/Inpria Corporation and Lam Research Enter Cross Licensing and Collaboration Agreement to Advance Semiconductor Manufacturing
Sep 16, 2025 09:00 JST
Toyota Launches Next-Generation New Mobility e-Palette
Sep 15, 2025 15:33 JST
The University of Osaka D3 Center Commences Operation of New Computing and Data Infrastructure Built by NEC
Sep 12, 2025 15:08 JST
GR Yaris "Aero performance package" Set for Japan Launch
Sep 12, 2025 14:40 JST
Mitsubishi Heavy Industries Achieves Target Performance at Pilot Plant for Bioethanol Membrane Dehydration Systems
Sep 12, 2025 14:19 JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sep 12, 2025 13:20 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Succeeds in Developing High-Performance Palladium Alloy Hydrogen Permeable Membrane Operable in the Low-Temperature Range of 300 degrees C
Sep 12, 2025 11:00 JST
More Latest Release >>